Number of children that contributed to the recommendations in the ASH 2018 guidelines (total number of reported children by study type in the literature up to 2018)
| Neonate to 18 y . | LMWH . | VKA . |
|---|---|---|
| DVT/PE RCT data | N=36 | N=40 |
| DVT/PE observational data | N=940 (recurrent DVT/major bleeding) | N=107 (recurrent DVT) N=590 (major bleeding) |
| CVC-associated VTE: from RCT | N=20 | N=29 |
| CVC associated: RA thrombosis | 28 observational studies N=30 | |
| CVST RCT data | Nil | Nil |
| CVST observational data | Children/neonates: 17 studies N=752 Neonates only: 6 studies N=127 | |
| Neonate to 18 y . | LMWH . | VKA . |
|---|---|---|
| DVT/PE RCT data | N=36 | N=40 |
| DVT/PE observational data | N=940 (recurrent DVT/major bleeding) | N=107 (recurrent DVT) N=590 (major bleeding) |
| CVC-associated VTE: from RCT | N=20 | N=29 |
| CVC associated: RA thrombosis | 28 observational studies N=30 | |
| CVST RCT data | Nil | Nil |
| CVST observational data | Children/neonates: 17 studies N=752 Neonates only: 6 studies N=127 | |
CSVT, cerebral sinovenous thrombosis; DVT, deep vein thrombosis; LMWH, low molecular weight heparin; PE, pulmonary embolus; RA, right atrium; RCT, randomized controlled trials; VKA, vitamin K antagonists.